ROME (MedPage Today) -- Nearly 70% of treatment-naive HIV-infected patients receiving the integrase inhibitor raltegravir (Isentress) maintained undetectable virus levels for 240 weeks, researchers reported here.
naive hivIAS: Raltegravir Remains Effective over Long Term (CME/CE)MedPage Today Infectious Disease Thu, 07/21/2011 - 15:05
Early Anti-HIV Therapy Benefits Opportunistic InfectionsMedPage Today Infectious Disease Wed, 03/25/2009 - 12:51
ATLANTA (MedPage Today) -- For treatment-naive HIV patients with an opportunistic infection, the benefits of immediate antiretroviral therapy outweigh the risks, according to new guidelines from the CDC. |
